Depression Clinical Trials in Arlington, TX

47 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression	—	University of Texas Southwestern Medical Center	<1 mi
Exploring Virtual Reality Adventure Training Exergaming	N/A	The University of Texas at Arlington	<1 mi
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)	Phase 2	Seaport Therapeutics	11 mi
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.	Phase 3	AbbVie	12 mi
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder	Phase 3	Neumora Therapeutics, Inc.	12 mi
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms	Phase 3	Janssen Research & Development, LLC	12 mi
Study to Assess the Safety and Effectiveness of NMRA-335140-501	Phase 3	Neumora Therapeutics, Inc.	12 mi
Study of ALTO-300 in MDD	Phase 2	Alto Neuroscience	12 mi
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder	Phase 3	Cybin IRL Limited	12 mi
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder	Phase 2	Syndeio Biosciences, Inc	18 mi
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)	Phase 2	atai Therapeutics, Inc.	18 mi
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression	Phase 2	Draig Therapeutics Ltd	18 mi
A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD)	—	Janssen Research & Development, LLC	18 mi
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)	Phase 3	Cybin IRL Limited	18 mi
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder With Comorbid Anxiety and Insomnia	Phase 2	Syndeio Biosciences, Inc	18 mi
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)	Phase 3	Definium Therapeutics US, Inc.	18 mi
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression	N/A	VA Office of Research and Development	18 mi
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder	Phase 3	Neumora Therapeutics, Inc.	18 mi
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression	N/A	LivaNova	18 mi
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	18 mi
Dallas 2K: A Natural History Study of Depression	—	University of Texas Southwestern Medical Center	18 mi
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)	N/A	Baylor College of Medicine	18 mi
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Phase 3	Neurocrine Biosciences	18 mi
DBS for Depression	N/A	Baylor College of Medicine	18 mi
Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care	N/A	Elizabeth Arnold	18 mi
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms	Phase 4	Axsome Therapeutics, Inc.	18 mi
Accelerated rTMS for Substance Use Disorder and Depression	N/A	University of Texas Southwestern Medical Center	18 mi
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services	—	Beth Israel Deaconess Medical Center	18 mi
Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)	N/A	Abbott Medical Devices	18 mi
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women	N/A	BTL Industries Ltd.	18 mi
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder	Phase 2	Sirtsei Pharmaceuticals, Inc.	18 mi
Preventing Vulnerable Child Syndrome in the NICU With Cognitive Behavioral Therapy (PreVNT Trial)	N/A	University of Texas Southwestern Medical Center	18 mi
Combination of Novel Therapies for CKD Comorbid Depression	Phase 2	Stony Brook University	18 mi
Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression	N/A	Nader Pouratian	18 mi
Recovery Through Inspiration, Support, and Empowerment	N/A	University of Texas Southwestern Medical Center	18 mi
Resilience in Adolescent Development	—	University of Texas Southwestern Medical Center	18 mi
Teen Recovery Through Inspiration, Support, and Empowerment	N/A	University of Texas Southwestern Medical Center	18 mi
Measurement-Based Peer Supervision App for Non-Specialist Providers	N/A	Dimagi Inc.	18 mi
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients	Phase 3	Intra-Cellular Therapies, Inc.	19 mi
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder	Phase 2	AbbVie	26 mi
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder	Phase 3	Vanda Pharmaceuticals	26 mi
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder	Phase 2	AbbVie	26 mi
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder	Phase 3	Intra-Cellular Therapies, Inc.	26 mi
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"	Phase 3	Cybin IRL Limited	31 mi
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder	Phase 3	Xenon Pharmaceuticals Inc.	31 mi
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age	—	State University of New York at Buffalo	31 mi
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder	Phase 2	Janssen Research & Development, LLC	43 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.